In that scenario: prep and sell (licence) individual indications, well, it's a business model that would appeal to bigger pharma also except they have the wherewithal to be selective in what they put on market. PYC would have to make sales because of the need for capital to advance other indications. I'm with Akki on this - cash - but they are doing everything right to position the company with multiple shots on goal/sale/licence. Congrats to management! Bringing Fletcher in was the company defining moment for mine.
PYC Price at posting:
18.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)